Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc. is a rare-disease biopharma name, and that already tells you the company lives in a narrow but serious part of medicine. By our assessment, its strength is focus: firms like this are built around a small number of specific therapeutic problems, so the science and the patient need stay close together. The downside is the usual one for this field — development is slow, evidence matters a lot, and the business can depend heavily on a single program or indication. In practice, that makes the story technical, carefully watched, and often hard for outsiders to read at a glance. It sits closer to specialty biotech than to broad consumer health or big, diversified pharma. The plain reason to value Soleno Therapeutics, Inc. is that it works in a place where ordinary drug companies often do not spend much effort, and that narrowness is both its strength and its ceiling.